Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist
Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. Ho...
Gespeichert in:
Veröffentlicht in: | Annales de biologie clinique (Paris) 2003-11, Vol.61 (6), p.645 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | 645 |
container_title | Annales de biologie clinique (Paris) |
container_volume | 61 |
creator | Parant, F Ducluzeau, R Lardet, G Gagnieu, M-C Moulsma, M |
description | Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments. |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_14711605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14711605</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-dac7c5bd2af9c9e45e307a2ca1e82ffe64669626d5fdb86c6ae14a0ad1f34f8b3</originalsourceid><addsrcrecordid>eNo1j81KAzEYAHNQbG19BckLLCSbn816K8WqUOil9_Il-ZJGdpNlN4K-vQftaQ4DA3NH1owx0QjTmxV5XJZPxnhrhHggKy47zjVTa3La5Zp8iuU7ZXoAS8MMccRcFwrZ05sZS061zCnHFwrUXWEYMEekocy0XpHaVIYS01K35D7AsODTPzfkfHg979-b4-ntY787NpOSqvHgOqesbyH0rkepULAOWgccTRsCaql1r1vtVfDWaKcBuQQGngchg7FiQ57_stOXHdFfpjmNMP9cbmPiF1ebSpA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</creator><creatorcontrib>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</creatorcontrib><description>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</description><identifier>ISSN: 0003-3898</identifier><identifier>PMID: 14711605</identifier><language>fre</language><publisher>France</publisher><subject>Aged ; Aged, 80 and over ; Digoxin - blood ; Digoxin - immunology ; Drug Monitoring - methods ; Female ; Humans ; Immunoglobulin Fab Fragments - therapeutic use ; Male ; Middle Aged ; Ultrafiltration</subject><ispartof>Annales de biologie clinique (Paris), 2003-11, Vol.61 (6), p.645</ispartof><rights>Copyright John Libbey Eurotext 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14711605$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parant, F</creatorcontrib><creatorcontrib>Ducluzeau, R</creatorcontrib><creatorcontrib>Lardet, G</creatorcontrib><creatorcontrib>Gagnieu, M-C</creatorcontrib><creatorcontrib>Moulsma, M</creatorcontrib><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><title>Annales de biologie clinique (Paris)</title><addtitle>Ann Biol Clin (Paris)</addtitle><description>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Digoxin - blood</subject><subject>Digoxin - immunology</subject><subject>Drug Monitoring - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ultrafiltration</subject><issn>0003-3898</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KAzEYAHNQbG19BckLLCSbn816K8WqUOil9_Il-ZJGdpNlN4K-vQftaQ4DA3NH1owx0QjTmxV5XJZPxnhrhHggKy47zjVTa3La5Zp8iuU7ZXoAS8MMccRcFwrZ05sZS061zCnHFwrUXWEYMEekocy0XpHaVIYS01K35D7AsODTPzfkfHg979-b4-ntY787NpOSqvHgOqesbyH0rkepULAOWgccTRsCaql1r1vtVfDWaKcBuQQGngchg7FiQ57_stOXHdFfpjmNMP9cbmPiF1ebSpA</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Parant, F</creator><creator>Ducluzeau, R</creator><creator>Lardet, G</creator><creator>Gagnieu, M-C</creator><creator>Moulsma, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200311</creationdate><title>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</title><author>Parant, F ; Ducluzeau, R ; Lardet, G ; Gagnieu, M-C ; Moulsma, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-dac7c5bd2af9c9e45e307a2ca1e82ffe64669626d5fdb86c6ae14a0ad1f34f8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2003</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Digoxin - blood</topic><topic>Digoxin - immunology</topic><topic>Drug Monitoring - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ultrafiltration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parant, F</creatorcontrib><creatorcontrib>Ducluzeau, R</creatorcontrib><creatorcontrib>Lardet, G</creatorcontrib><creatorcontrib>Gagnieu, M-C</creatorcontrib><creatorcontrib>Moulsma, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Annales de biologie clinique (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parant, F</au><au>Ducluzeau, R</au><au>Lardet, G</au><au>Gagnieu, M-C</au><au>Moulsma, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist</atitle><jtitle>Annales de biologie clinique (Paris)</jtitle><addtitle>Ann Biol Clin (Paris)</addtitle><date>2003-11</date><risdate>2003</risdate><volume>61</volume><issue>6</issue><spage>645</spage><pages>645-</pages><issn>0003-3898</issn><abstract>Following administration of anti-digoxin Fab fragments, monitoring unbound digoxin concentrations may help ensure appropriate dosing, and prevent recrudescent toxicity. Ultrafiltration by using Centrifree system and measurement of digoxin in the ultrafiltrate is considered as reference technique. However, ultrafiltration method is cumbersome, costly, and some immunoassays are affected by matrix differences. Another approach is to analyse the serum directly by digoxin immunoassays without ultrafiltering it. The validity of results obtained depends on the architecture of the immunoassay and the amount of Fab in the sample. The old radioimmunoassays and usually the other competitive immunoassays give inaccurate results. The fluorescence polarization immunoassay (FPIA) slightly underestimates the total digoxin concentrations. Total digoxin levels obtained at 24 hours and 48 hours after treatment permit measurement of the half-life of digoxin Fab complexes and can be used to estimate when the patient can be redigitalized, if necessary. The sequential immunoassays usually overestimate the free digoxin concentrations. The differences observed are >25% and cannot be explained solely by albumin binding (normal range, 20% +/- 5%). To date, ultrafiltration remains the best strategy for accurate determination of digoxin concentrations in the presence of antidigoxin Fab fragments.</abstract><cop>France</cop><pmid>14711605</pmid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-3898 |
ispartof | Annales de biologie clinique (Paris), 2003-11, Vol.61 (6), p.645 |
issn | 0003-3898 |
language | fre |
recordid | cdi_pubmed_primary_14711605 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Aged Aged, 80 and over Digoxin - blood Digoxin - immunology Drug Monitoring - methods Female Humans Immunoglobulin Fab Fragments - therapeutic use Male Middle Aged Ultrafiltration |
title | Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antidigoxin%20Fab%20fragments%20and%20digoxin%20monitoring:%20a%20challenge%20for%20the%20biologist&rft.jtitle=Annales%20de%20biologie%20clinique%20(Paris)&rft.au=Parant,%20F&rft.date=2003-11&rft.volume=61&rft.issue=6&rft.spage=645&rft.pages=645-&rft.issn=0003-3898&rft_id=info:doi/&rft_dat=%3Cpubmed%3E14711605%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14711605&rfr_iscdi=true |